Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
- Eric Jonasch
- , Todd M. Bauer
- , Kyriakos P. Papadopoulos
- , Elizabeth R. Plimack
- , Jaime R. Merchan
- , David F. McDermott
- , M. Dror Michaelson
- , Leonard J. Appleman
- , Ananya Roy
- , Rodolfo F. Perini
- , Yanfang Liu
- , Toni K. Choueiri
- University of Texas MD Anderson Cancer Center
- Tennessee Oncology
- South Texas Accelerated Research Therapeutics
- University of Miami
- Beth Israel Deaconess Medical Center
- Massachusetts General Hospital
- University of Pittsburgh
- Merck & Co.
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
24
Scopus
citations